PMID- 21188103
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 2
DP  - 2010 May 24
TI  - Management of metastatic renal cell carcinoma in patients with poor prognosis.
PG  - 123-32
AB  - An improved understanding of renal cell carcinoma (RCC) biology has translated 
      into major advances in the treatment of patients with metastatic RCC in recent 
      years. Clinical and pathologic criteria can be used to identify RCC patients with 
      poor prognoses. Such patients, however, are often excluded from the cancer 
      clinical trials that guide treatment recommendations. This article reviews 
      available information on the management of patients with metastatic RCC and poor 
      risk features, focusing on the role of vascular endothelial growth factor (VEGF) 
      pathway and mammalian target of rapamycin (mTOR) inhibitors. While patients with 
      poor risk features have a more guarded outcome, treatment with temsirolimus has 
      produced meaningful improvements in overall survival for this population. 
      Definitive phase III trial data are lacking for the VEGF pathway inhibitors in 
      patients with poor prognostic features. However, available data suggest that such 
      patients tolerate VEGF pathway blockade reasonably well and are likely to achieve 
      some benefit relative to treatment with interferon. Ongoing translational 
      research efforts may help to define novel treatment approaches specific for 
      patients with metastatic RCC and poor prognostic features.
FAU - Bullock, Andrea
AU  - Bullock A
AD  - Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, 
      MA, USA.
FAU - McDermott, David F
AU  - McDermott DF
FAU - Atkins, Michael B
AU  - Atkins MB
LA  - eng
PT  - Journal Article
DEP - 20100524
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC3004580
OTO - NOTNLM
OT  - mammalian target of rapamycin (mTOR) inhibitors
OT  - prognostic criteria
OT  - renal cell carcinoma
OT  - vascular endothelial growth factor (VEGF)-pathway inhibitors
EDAT- 2010/12/29 06:00
MHDA- 2010/12/29 06:01
PMCR- 2010/05/24
CRDT- 2010/12/29 06:00
PHST- 2010/05/22 00:00 [received]
PHST- 2010/12/29 06:00 [entrez]
PHST- 2010/12/29 06:00 [pubmed]
PHST- 2010/12/29 06:01 [medline]
PHST- 2010/05/24 00:00 [pmc-release]
AID - cmr-2-123 [pii]
PST - epublish
SO  - Cancer Manag Res. 2010 May 24;2:123-32.